Stay updated on Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The study record for pembrolizumab combined with doxorubicin in advanced endometrial cancer is displayed, including its eligibility criteria, treatment plan, outcomes, study locations, and record dates.
    Difference
    45%
    Check dated 2026-11-08T11:28:11.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T12:21:45.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T12:29:59.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1. The page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T13:23:07.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The site footer revision number changed from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:15:22.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the usual study record content. This indicates an access restriction or server-side issue preventing viewing the NCT03276013 details.
    Difference
    17%
    Check dated 2026-09-20T15:35:25.000Z thumbnail image

Stay in the know with updates to Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.